4390 U.S. Route One North
Princeton, NJ 08540
Phone: 609-750-2200
www.orchid.com

Dale Pfost, president and CEO
NASDAQ:ORCH

Overview

Founded in 1995, Orchid BioSciences is a leading provider of products and services for single nucleotide polymorphism scoring and genetic diversity analysis. The company has developed SNP-IT a proprietary SNP analysis technology, and markets SNPstream instruments and SNPware consumables. The company provides high-throughput SNP scoring services through its MegaSNPatron facilities. The company is seeking to identify proprietary medical applications of SNPs through its Pharmaceutical Value Creation business segment.

The company acquired Lifecodes Corp. in October 2001 to solidify its place the field of identity genomics, used in forensics and paternity cases. Based on Orchid's stock price at the time, the acquisition was valued at about $12.7 million. Lifecodes’ Cellmark unit has been used by law enforcement in the Unabomber and O.J. Simpson trials. The company also conducts DNA testing at its GeneScreen facility.

Partners

GlaxoSmithKline plc for SNP validation for pharmacogenetics.

Ellipsis Biotherapeutics in SNPs and pharmacogenomics.

Affymetrix Inc. to combine Orchid’s primer extension technology with Affymetrix’s chip technology.

Orchid also is partnered with AstraZeneca plc, Eli Lilly and Co., Exelixis Inc., Bristol-Myers Squibb Co., GlaxoSmithKline plc and DNAPrint Genomics Inc., among others.